DarioHealth Corp. (NASDAQ:DRIO) Stock Rated “Hold” by Sell-Side Analysts

DarioHealth Corp. (NASDAQ:DRIO) has been assigned an average rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.00.

DRIO has been the topic of a number of research analyst reports. BTIG Research initiated coverage on shares of DarioHealth in a report on Tuesday, October 27th. They set a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a report on Tuesday, October 6th. Alliance Global Partners started coverage on shares of DarioHealth in a research report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, TD Cowen cut their price target on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th.

DarioHealth Price Performance

Shares of NASDAQ:DRIO opened at $3.03 on Tuesday. DarioHealth has a 1 year low of $2.95 and a 1 year high of $14.77. The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average is $5.90 and its two-hundred day moving average is $7.75.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.37. The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. Analysts anticipate that DarioHealth will post -2.94 EPS for the current year.

Hedge Funds Weigh In On DarioHealth

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new position in DarioHealth during the second quarter worth $4,030,561. Commonwealth Equity Services LLC purchased a new position in DarioHealth in the third quarter worth $159,000. Finally, BlackRock Inc. acquired a new stake in DarioHealth in the second quarter valued at $249,000. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.

The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.